About Covidien Ltd (NYSE:COV)
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:COV
- CUSIP: G2554F11
- Web: N/A
- Trailing P/E Ratio: N/A
- P/E Growth: 0
- Net Margins: 19.02%
- Return on Equity: 20.06%
- Return on Assets: 9.92%
Frequently Asked Questions for Covidien Ltd (NYSE:COV)
What is Covidien Ltd's stock symbol?
Covidien Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "COV."
How were Covidien Ltd's earnings last quarter?
Covidien Ltd (NYSE:COV) released its earnings results on Wednesday, November, 5th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.13. The business had revenue of $2.73 billion for the quarter, compared to analyst estimates of $2.69 billion. Covidien Ltd had a return on equity of 20.06% and a net margin of 19.02%. Covidien Ltd's revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.91 earnings per share. View Covidien Ltd's Earnings History.
Who are some of Covidien Ltd's key competitors?
Some companies that are related to Covidien Ltd include Baxter International (BAX), Zimmer Biomet Holdings (ZBH), C.R. Bard (BCR), Align Technology (ALGN), DENTSPLY SIRONA (XRAY), Steris Plc (STE), West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), DexCom (DXCM), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), NuVasive (NUVA), Nevro Corp. (NVRO) and Haemonetics Corporation (HAE).
Who are Covidien Ltd's key executives?
Covidien Ltd's management team includes the folowing people:
- Gary L. Ellis, President, Chief Executive Officer
- Charles J. Dockendorff, Chief Financial Officer, Executive Vice President
- Bryan C. Hanson, Group President, Covidien
- John H. Masterson, Senior Vice President, General Counsel
- Michael P. Dunford, Senior Vice President - Human Resources
- James C. Clemmer, Senior Vice President and President - Medical Supplies Business
- Amy A. McBride-Wendell, Senior Vice President - Strategy and Business Development
- Jacqueline F. Strayer, Senior Vice President-Corporate Communications
- Michael E. Tarnoff, Senior Vice President,Chief Medical Officer
- Peter L. Wehrly, Senior Vice President, Group President - Developed Markets
How do I buy Covidien Ltd stock?
Shares of Covidien Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Covidien Ltd's stock price today?
MarketBeat Community Rating for Covidien Ltd (NYSE COV)MarketBeat's community ratings are surveys of what our community members think about Covidien Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Covidien Ltd stock can currently be purchased for approximately $108.07.
Consensus Ratings for Covidien Ltd (NYSE:COV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Covidien Ltd (NYSE:COV)
Analysts' Ratings History for Covidien Ltd (NYSE:COV)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Covidien Ltd (NYSE:COV)Earnings History by Quarter for Covidien Ltd (NYSE COV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/22/2015||Q115||$1.04||$1.11||$2.72 billion||$2.69 billion||View||N/A|
|11/5/2014||Q414||$1.02||$1.15||$2.69 billion||$2.73 billion||View||Listen|
|7/25/2014||Q314||$1.00||$1.04||$2.69 billion||$2.69 billion||View||Listen|
|4/25/2014||Q214||$0.95||$0.96||$2.61 billion||$2.60 billion||View||Listen|
|1/24/2014||Q114||$0.94||$1.00||$2.61 billion||$2.64 billion||View||Listen|
|8/1/2013||Q3 2013||$0.89||$0.85||$2.58 billion||$2.58 billion||View||Listen|
|4/26/2013||Q2 2013||$1.09||$1.12||$3.12 billion||$3.10 billion||View||Listen|
|1/25/2013||Q1 2013||$1.06||$1.10||$3.00 billion||$3.06 billion||View||Listen|
|11/9/2012||Q412||$1.00||$1.02||$2.98 billion||$3.00 billion||View||N/A|
Earnings Estimates for Covidien Ltd (NYSE:COV)
Current Year EPS Consensus Estimate: $0.00 EPS
Next Year EPS Consensus Estimate: $0.00 EPS
Current Dividend Information for Covidien Ltd (NYSE:COV)
|Most Recent Dividend:||1/16/2015|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||NaN (Based on This Year's Estimates)|
NaN (Based on Next Year's Estimates)
|Track Record:||8 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Covidien Ltd (NYSE COV)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Covidien Ltd (NYSE:COV)Insider Trades by Quarter for Covidien Ltd (NYSE:COV)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/5/2014||Michael Sgrignari||SVP||Sell||25,795||$103.48||$2,669,266.60|| |
|12/3/2014||Dennis H Reilley||Director||Sell||10,521||$101.39||$1,066,724.19|| |
|11/17/2014||Richard G Brown Jr||VP||Buy||5,300||$94.44||$500,532.00|| |
|11/7/2014||Robert H Brust||Director||Sell||4,000||$92.03||$368,120.00|| |
|8/27/2014||Coleman N Lannum III||VP||Buy||3,338||$87.23||$291,173.74|| |
|8/26/2014||Coleman N Lannum III||VP||Buy||1,736||$87.46||$151,830.56|| |
|8/19/2014||Coleman N Lannum III||VP||Buy||1,720||$87.82||$151,050.40|| |
|8/18/2014||Coleman N Lannum III||VP||Buy||4,100||$87.58||$359,078.00|| |
|6/16/2014||Jose E Almeida||Insider||Sell||51,166||$92.05||$4,709,830.30|| |
|4/29/2014||Brian Douglas King||VP||Sell||15,569||$70.11||$1,091,542.59|| |
|3/28/2014||Charles Dockendorff||CFO||Sell||90,730||$72.50||$6,577,925.00|| |
|2/28/2014||Jose Almeida||Insider||Sell||50,000||$72.00||$3,600,000.00|| |
|2/13/2014||Richard Brown, Jr.||VP||Sell||4,000||$71.00||$284,000.00|| |
|2/11/2014||Brian Douglas King||VP||Sell||17,946||$70.00||$1,256,220.00|| |
|2/11/2014||Bryan Hanson||SVP||Sell||32,480||$69.97||$2,272,625.60|| |
|1/29/2014||Coleman Lannum III||VP||Sell||13,787||$69.23||$954,474.01|| |
|1/24/2014||Richard Brown, Jr.||VP||Sell||4,000||$70.00||$280,000.00|| |
Headline Trends for Covidien Ltd (NYSE:COV)
Latest Headlines for Covidien Ltd (NYSE:COV)
Covidien Ltd (COV) Chart for Friday, October, 20, 2017